Cambridge, UK; 10th July, 2020.
We are delighted to announce that Toby Wilson Waterworth, CEO Atlantic Healthcare plc, (“Atlantic Healthcare” or “Company”) has been invited to join the panel of speakers at the Virtual 2020 BMG Economic Forum, on 15th July, 2020.
This prestigious, annual event is a platform to discuss opportunities in and around Saudi Arabia. The 2020 theme is ‘Moving Forward: Investment Opportunities in Saudi Arabia & Beyond’.
Atlantic Healthcare is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases. The Company plans to market its products itself in the U.S. and Europe, and partner with established pharmaceutical companies to commercialize its products in the rest of the world, including the Middle East.
Toby is joining the panel discussing Opportunities in Saudi Healthcare and Pharmaceutical Industry – Privatisation, Partnerships and Digitisation, between 16:15 and 16:55 (BST).
This influential event, which normally takes place at a venue in London, brings together a unique gathering of Royal Family Members, senior government officials, CEOs and senior executives from Saudi Arabia, the UK and Europe to discuss investment and partnership opportunities. This year, in response to Covid-19, it is being hosted online and will conclude with an orchestra featuring the G20 countries broadcasting live from the iconic Wiener Musikverein concert hall.
Details of BMG Virtual Economic Forum can be found here. If you are interested in attending the event to hear Toby speak, please email Forum@bmg.com.sa
About Atlantic Healthcare
Atlantic Healthcare plc (https://www.atlantichc.com/) is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.
The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders.
Led by an experienced international Board and Leadership Team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare plans to commercialize its products in the U.S. and Europe using a specialist sales team targeting healthcare professionals based in hospitals and specialist care centers. The Company plans to partner with established pharmaceutical companies to commercialize its products in the rest of the world, including the Middle East.
Forward Looking Statements
While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.
For more information about Atlantic Healthcare, investment, alicaforsen or renzapride, please contact:
Adam Michael (Head of Communications)
+44 1799 512 055
+44 777 588 1813